Controlled energy delivery
Safe, effective procedures
Jeremy N. Ruskin, MD
Founder and Director Emeritus;
Cardiac Arrhythmia Service, Massachusetts General Hospital;
Professor of Medicine, Harvard Medical School
“Ablacor’s novel approach of a circular ablator, with its controlled electrode-tissue contact, designed to generate continuous and transmural ablation lesions reliably, holds great promise and would be a major advance.”
AblaCor™ Medical Corporation’s mission is to develop innovative products to significantly advance Atrial Fibrillation (AFib) treatment. The Company’s goal is to provide patients with long-term freedom from AFib without multiple ablation procedures.
AblaCor’s first product, the CircumBlator™ AF Catheter Ablation System, is uniquely designed to deliver pulmonary vein isolation (PVI) in a “single-shot" circumferential ablation compared to currently marketed “point-by-point” and “balloon” technologies.
AblaCor's Scientific Advisors
The CircumBlator™ AF Catheter Ablation System is not approved for human use.
Lawrence S. Rosenthal MD, PhD, FACC, FHRS
Director, Electrophysiology Service;
Professor of Medicine, UMass Memorial Medical Center
Continuous tissue contact for precise lesion formation the first time
Improved patient outcomes
Fewer repeat procedures
Reduced healthcare costs